scholarly journals Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase‐positive non‐small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report

2021 ◽  
Vol 9 (7) ◽  
Author(s):  
Kota Sasaki ◽  
Yusuke Yokota ◽  
Toshihito Isojima ◽  
Mayumi Fujii ◽  
Kengo Hasui ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Anaplastic Lymphoma Kinase ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Carcinomatous Meningitis ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma

scholarly journals Promising Effect of Crizotinib on Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer in an Elderly Patient with a Poor Performance Status: A Case Report and Literature Review

2016 ◽  
Vol 55 (5) ◽  
pp. 507-509 ◽  
Author(s):  
Norikazu Matsuo ◽  
Akimasa Sekine ◽  
Terufumi Kato ◽  
Chiaki Hosoda ◽  
Hiroyuki Ito ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Elderly Patient ◽  
Case Report ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Alk Positive

scholarly journals Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutation in a Patient with a Poor Performance Status: A Case Report

2021 ◽  
Vol Volume 14 ◽  
pp. 5315-5319
Author(s):  
Yuki Kato ◽  
Yasuhiro Kato ◽  
Yuji Minegishi ◽  
Takahiro Suzuki ◽  
Shinji Nakamichi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Report ◽  
Small Cell Lung Cancer ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Insertion Mutation ◽  
Small Cell Lung ◽  
Exon 20

scholarly journals Clinical Benefit of Chemotherapy for Small-Cell Lung Cancer Patients with Extremely Poor Performance Status (PS)

2018 ◽  
Vol 26 (1) ◽  
pp. 1-6
Author(s):  
Ou Yamaguchi ◽  
Hiroshi Kagamu ◽  
Atsuto Mouri ◽  
Ayako Shiono ◽  
Harue Utsugi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Clinical Benefit ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Lung Cancer Patients

scholarly journals Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chiao-En Wu ◽  
Ching-Fu Chang ◽  
Chen-Yang Huang ◽  
Cheng-Ta Yang ◽  
Chih-Hsi Scott Kuo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Disease Control ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Nsclc Patients

Abstract Background Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥ 2) are limited. This study aimed to retrospectively review the clinical outcomes and safety of afatinib treatment in EGFR-mutation-positive (EGFRm+) NSCLC patients with PS ≥ 2. Methods The data for 62 patients who were treated at Linkou Chang Gung Memorial Hospital from January 2010 to August 2019 were retrospectively reviewed. Patients’ clinicopathological features were obtained, and univariate and multivariate analyses were performed to identify possible prognostic factors. Data on adverse events were collected to evaluate general tolerance for afatinib therapy. Results Until February 2020, the objective response rate, disease control rate, median progression-free survival (PFS), and overall survival (OS) were 58.1% (36/62), 69.4% (43/62), 8.8 months, and 12.9 months, respectively. The absence of liver metastasis (PFS: p = 0.044; OS: p = 0.061) and good disease control (p < 0.001 for PFS and OS) were independent favorable prognostic factors for PFS and OS. Bone metastasis (p = 0.036) and dose modification (reduction/interruption, p = 0.021) were predictors of disease control. Conclusion Afatinib demonstrated acceptable efficacy and safety in the current cohort. This study provided evidence to support the use of afatinib as a first-line treatment in EGFRm+ NSCLC patients with poor PS.

ACR Appropriateness Criteria® on Nonsurgical Treatment for Non–Small-Cell Lung Cancer: Poor Performance Status or Palliative Intent

2009 ◽  
Vol 6 (2) ◽  
pp. 85-95 ◽  
Author(s):  
Kenneth E. Rosenzweig ◽  
Benjamin Movsas ◽  
Jeff Bradley ◽  
Richard M. Gewanter ◽  
Ramesh S. Gopal ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Performance Status ◽  
Poor Performance ◽  
Small Cell ◽  
Poor Performance Status ◽  
Small Cell Lung ◽  
Appropriateness Criteria ◽  
Palliative Intent ◽  
Acr Appropriateness Criteria
Sign in / Sign up

Export Citation Format

Share Document